{
    "clinical_study": {
        "@rank": "16498", 
        "acronym": "ABO ONA", 
        "arm_group": [
            {
                "arm_group_label": "group A", 
                "arm_group_type": "Active Comparator", 
                "description": "Group A: Patients received 2units/0.02 mL of reconstituted ABO on the right side of the forehead and 2 units/0.02 mL of reconstituted ONA on the left side."
            }, 
            {
                "arm_group_label": "group B", 
                "arm_group_type": "Active Comparator", 
                "description": "Patients received 2units/0.02 mL of reconstituted ABO on the left side of the forehead and 2 units/0.02 mL of reconstituted ONA on the right side."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess the fields of effect (FE) of ABO and ONA at the same\n      labeled unit dose (1:1 units), comparing both sweat gland and muscle activity."
        }, 
        "brief_title": "Fields Of Effects Of Two Commercial Preparations Of Botulinum Toxin Type A At Equal Labeled Unit Doses", 
        "completion_date": {
            "#text": "November 2012", 
            "@type": "Actual"
        }, 
        "condition": "Healthy Subjects, Only With Wrinkles on Forehead.", 
        "detailed_description": {
            "textblock": "This is a prospective, single-center, randomized, double-blind study. All participants will\n      be recruited from a research center in Porto Alegre, Brazil, and provided written informed\n      consent. This study will be approved by the local Ethics Committee of Associa\u00e7\u00e3o Hospitalar\n      Moinhos de Vento and all Good Clinical Practices, Declaration of Helsinki protocols and\n      national regulations were followed. The main inclusion criteria are: female subjects aged\n      between 18 to 60 years; presence of moderate to severe forehead wrinkles on both sides at\n      maximum contraction of frontalis muscle according to Wrinkle Severity Scores (WSS) (Hexsel\n      et al., 2012); positive sweating by the Minor's Test (Minor, 1927) and scores from III to V\n      on the Sweat Intensity Visual Scale (Hexsel et al., 2010)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  female subjects aged between 18 to 60 years;\n\n          -  presence of moderate to severe forehead wrinkles on both sides at maximum contraction\n             of frontalis muscle according to Wrinkle Severity Scores (WSS) (Hexsel et al., 2012);\n\n          -  positive sweating by the Minor's Test (Minor, 1927) and scores from III to V on the\n             Sweat Intensity Visual Scale (Hexsel et al., 2010).\n\n        Exclusion Criteria:\n\n          -  none"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 7, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01732809", 
            "org_study_id": "11-2011"
        }, 
        "intervention": [
            {
                "arm_group_label": "group A", 
                "description": "isovolumetric (0.02 mL) doses of 2 units of ABO injected on one side of the forehead and 2 units of ONA injected on the contralateral side", 
                "intervention_name": "group A", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Dysport\u00ae (AbotulinumtoxinA; ABO),", 
                    "Botox\u00ae (OnabotulinumtoxinA; ONA)"
                ]
            }, 
            {
                "arm_group_label": "group B", 
                "description": "Patients received 2units/0.02 mL of reconstituted ABO on the left side of the forehead and 2 units/0.02 mL of reconstituted ONA on the right side.", 
                "intervention_name": "group B", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Dysport\u00ae (AbotulinumtoxinA; ABO),", 
                    "Botox\u00ae (OnabotulinumtoxinA; ONA)"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Botulinum Toxins, Type A", 
                "Botulinum Toxins"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "wrinkles", 
            "botulinum toxin"
        ], 
        "lastchanged_date": "November 28, 2012", 
        "location": {
            "facility": {
                "address": {
                    "city": "Porto Alegre", 
                    "country": "Brazil"
                }, 
                "name": "CBED"
            }
        }, 
        "location_countries": {
            "country": "Brazil"
        }, 
        "number_of_arms": "2", 
        "official_title": "FIELDS OF EFFECTS OF TWO COMMERCIAL PREPARATIONS OF BOTULINUM TOXIN TYPE A AT EQUAL LABELED UNIT DOSES", 
        "overall_official": {
            "affiliation": "CBED", 
            "last_name": "Doris m Hexsel, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Brazil: Local Ethic Committee", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "October 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Field effect characteristics of ABO and ONA at the same dose (1:1 labeled unit equivalence) regarding both muscle and sweat gland activities.", 
            "measure": "Field effect", 
            "safety_issue": "No", 
            "time_frame": "1 time"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01732809"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Brazilan Center for Studies in Dermatology", 
            "investigator_full_name": "Doris Hexsel", 
            "investigator_title": "MD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Brazilan Center for Studies in Dermatology", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Brazilan Center for Studies in Dermatology", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)", 
        "study_type": "Interventional", 
        "verification_date": "November 2012"
    }
}